|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: HIV Therapy Dynamics
Datamonitor, Oct 2007, Pages: 190
Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HIV has continued to increase across the 6MM.
However, significant advances in HIV disease understanding, treatment and management mean that the outlook for patients has considerably improved.
Scope
- Current epidemiology of HIV in the six major markets, including prevalence, diagnosis rates and patients split by line of therapy and drug regimens.
- A detailed examination of the patient numbers on each line of therapy, their drug regimens and preferences.
- Evaluation of the factors determining prescription choices and their respective level of influence.
- An assessment of the perception of new products in development and of key unmet needs within HIV.
Highlights
In the US and M5EU the total number of people living with HIV is continuing to increase. According to the physician survey, the total number of diagnosed patients across the 6MM is 1.1 million, of which 18% are treatment-naïve and approx. 800.000 are currently receiving therapy.
The complexity of HAART begins to increase as patients progress to later stages of therapy, with regimens consisting of up to 6 different drugs. Treatment also becomes much more individualized: This research shows that the top 5 most popular regimens selected by physicians account for only 13% of patients in salvage therapy.
Prescription choice is largely driven by patient and product-specific qualities, but the influence of these issues varies according to line of therapy. Efficacy and resistance profile exert an increasing influence as the patient becomes more treatment-experienced.
Reasons to Purchase
- Identify the key factors underlying prescription choice for treatment of HIV.
- Examine the current unmet needs in the HIV market and identify opportunities for new product development.
- Enhance your commercial positioning through an improved understanding of the HIV market dynamics.
Customers who bought this item also bought
Commercial Insight: HIV - Reshaping Treatment Paradigms
Pipeline Insight: HIV - Extending Treatment Options
Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential to progress treatment dynamics
Pipeline Insight: HIV - The Age of Convenience
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Stakeholder Insight: Inflammatory Bowel Disease - Debate over early aggressive treatment continues
Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need
Cell Therapy - Technologies, Markets and Companies
Chinese Markets for HIV Treatment Drugs
Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence
The Global HIV/AIDS Market Outlook to 2012
Selzentry™ (maraviroc) HIV Treatment: A Panel Discussion among Five HIV Specialists Prepared by Panel Intelligence, LLC
|
|
|
|
